on different races and ethnicities. We agree to this point and re-analyze the relationship of HLA-B27 and clinical characters in AS patients. Based on different races, the results of our analyses showed that there was a positive relation between HLA-B27 and sex [East Asia: RR (95% CI) = 1.05 (1.00, 1.10), P = 0.033], family history [East Asia: RR (95% CI) = 1.09 (1.05, 1.13), P < 0.001; Southwest Asia: RR (95% CI) = 1.69 (1.30, 2.22), P < 0.001], uveitis [East Asia: RR (95% CI) = 1.05 (1.01, 1.09), P = 0.008; Southwest Asia: RR (95% CI) = 1.46 (1.08, 1.96), P = 0.013] and peripheral joint involvement [Southwest Asia: RR (95% CI) = 1.74 (1.30, 2.34), P < 0.001]. However, as the limitations of eligible studies, it is difficult to conduct subgroup analysis for the relationships of HLA-B27 subtypes and clinical parameters in AS patients. Therefore, more relevant studies should be conducted to identify these results.
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Thanks for the advices suggested from this letter. Best regards, Dr. Lin. Secondly, this letter argues that the missed studies may affect the consequence of our study. After we reviewed these two articles, we do not suggest to include these two studies. In our study, we aimed at exploring the sensitivity of AS patients to HLA-B27, so we only selected studies including AS patients and their control normal groups. As to the relationships of clinical features and HLA-B27 and its subtypes in AS patients, we also follow the same criteria. However, the patients included in these two studies are both AS patients without control groups. And we also find the same problem related to the associations between HLA-B27 subtypes and clinical features in AS patients. Overall, we do not consider these studies to be involved.
Thirdly, this letter also suggests that we should perform subgroup analysis for clinical features of AS patients based
